CYPHERPUNK TECHNOLOGIES INC. Cash and Restricted Cash
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Cash and Restricted Cash of $7.62 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.62M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.69M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.04M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.69M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $7.62M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $6.69M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $14.04M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $9.69M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $18.13M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $32.71M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $47.25M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $62.82M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $78.48M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $54.92M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $70.64M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $80.74M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $91.42M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $102.04M 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $65.50M 10-K · filed 2025-03-26 | |
| 2022-09-30 | $78.31M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $90.88M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $103.22M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $114.92M 10-K · filed 2024-03-18 | |
| 2021-09-30 | $124.77M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $35.73M 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $43.49M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $52.07M 10-K · filed 2023-03-24 | |
| 2020-09-30 | $52.07M 10-Q · filed 2021-11-12 | $57.98M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $64.89M 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $25.46M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $3.89M 10-K · filed 2022-03-11 | |
| 2019-09-30 | $10.06M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $15.75M 10-Q · filed 2020-08-13 | |
| 2019-03-31 | $21.71M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $16.28M 10-K · filed 2021-03-12 | |
| 2018-09-30 | $23.25M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $30.48M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $35.38M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $25.74M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $14.20M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $17.17M 10-Q · filed 2018-08-08 | |
| 2017-03-31 | $23.80M 10-Q/A · filed 2018-08-08 | |
| 2016-12-31 | $793.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |